What is CTMX stock price today?

CTMX (CytomX Therapeutics Inc) stock is trading at $5.37 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CTMX stock going up or down today?

CTMX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CTMX stock now?

The decision to buy CTMX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CTMX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CTMX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CTMX stock overvalued or undervalued?

CTMX currently trades at a P/E ratio of 17.97 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if CTMX is fairly priced.

What is CTMX's P/E ratio?

CTMX has a price-to-earnings (P/E) ratio of 17.97, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is CTMX's market cap?

CTMX (CytomX Therapeutics Inc) has a market capitalization of $0.91 billion, making it a small-cap stock.

What is CTMX's price to book ratio?

CTMX trades at a price-to-book (P/B) ratio of 8.50, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CTMX pay dividends?

CTMX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CTMX's dividend yield?

CTMX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CTMX stock a good long-term investment?

CTMX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CTMX's revenue growth rate?

CTMX has shown revenue growth of -0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, CTMX is profitable with a profit margin of 0.2%. This indicates the company generates 0.2 cents of profit for every dollar of revenue.

What are the risks of investing in CTMX?

Key risks for CTMX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CTMX compare to its competitors?

Compare CTMX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CTMX's performance and positioning.

What is CTMX's stock price target for 2026?

Our AI model provides price targets for CTMX based on fundamental analysis: Bull case $6.98 (+30%), Base case $6.18 (+15%), Bear case $4.83 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CTMX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CTMX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CTMX's next earnings report?

CTMX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CTMX - CytomX Therapeutics Inc

NYSE * Healthcare * Biotechnology

$5.37

$-0.02 (-0.37%)

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

CTMX Key Statistics

Market Cap

$913.26M

P/E Ratio

17.97

P/B Ratio

8.50

EPS

$0.30

Revenue Growth

-0.8%

Profit Margin

0.2%

Employees

119

How CTMX Compares to Peers

CTMX is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CTMX(This stock)	$913.26M	18.0	-1%	0.2%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

CytomX Therapeutics Inc Company Information

Headquarters: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, undefined
Website: www.cytomx.com
Sector: Healthcare
Industry: Biotechnology

CTMX - CytomX Therapeutics Inc

About CytomX Therapeutics Inc

CTMX Key Statistics

How CTMX Compares to Peers

CytomX Therapeutics Inc Company Information

CTMX Lician Score

CTMX Financial Snowflake

Upcoming Events for CTMX